Natural small molecules that protect the spine from harmful calcium buildup
The role of endogenous low molecular weight mineralization inhibitors in spine health
This research looks at natural small molecules that may stop harmful calcium deposits in spinal discs to help people with degenerative back or neck problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11231254 on NIH RePORTER |
What this research studies
If you have chronic back or neck pain, this research studies how tiny natural compounds in the body prevent unwanted calcium crystals from forming in spinal joints and intervertebral discs. The team will analyze those low-molecular-weight substances and related proteins using lab experiments and animal models, and may examine human tissue samples where available. They will study how these molecules work and whether their loss or change contributes to disc degeneration and ectopic mineralization. The goal is to identify markers and pathways that could lead to treatments to protect the spine.
Who could benefit from this research
Good fit: People with degenerative intervertebral disc disease, chronic low back or neck pain, or imaging evidence of disc calcification would be the most relevant candidates.
Not a fit: People whose symptoms come from causes unrelated to disc mineralization—such as isolated muscle pain, recent acute injury, or nerve problems without calcification—may not benefit directly.
Why it matters
Potential benefit: Could point to new ways to prevent or treat disc calcification and reduce chronic back or neck pain.
How similar studies have performed: Related work on protein inhibitors of calcification (for example fetuin-A and Matrix Gla Protein) has shown protective effects in lab and animal studies, while studying low-molecular-weight inhibitors in spinal discs is a newer direction.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Van de Wetering, Koen — Thomas Jefferson University
- Study coordinator: Van de Wetering, Koen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.